SCHEMBL30348774

SCHEMBL30348774

CC(=O)N1CC2(CCC(Nc3ncc4c(-c5ccc6nccnc6c5)c[nH]c4n3)CC2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 2/20 0.38
▸ CLK2 P49760 1/20 0.38
▸ CLK3 P49761 1/20 0.38
▸ MAP3K11 Q16584 2/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ DYRK1B Q9Y463 1/20 0.37
▸ FLT3 P36888 1/20 0.35
▸ JUN P05412 7/20 0.35
▸ MAPK8 P45983 7/20 0.35
▸ MAPK9 P45984 7/20 0.35
▸ CDK2 P24941 7/20 0.35
▸ MAPK10 P53779 4/20 0.35
▸ CCNK O75909 2/20 0.35
▸ CDK12 Q9NYV4 2/20 0.35
▸ TDO2 P48775 1/20 0.34
▸ CDK6 Q00534 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDC7 O00311 1/20 0.34
▸ DBF4 Q9UBU7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25522659 1.00 DYRK1A (0.38) DYRK1ACLK2CLK3MAP3K11BRD4
SCHEMBL30347891 0.89 MAP3K11 (0.44) DYRK1ACLK2CLK3MAP3K11DYRK1B
SCHEMBL25522650 0.89 MAP3K11 (0.44) DYRK1ACLK2CLK3MAP3K11DYRK1B
SCHEMBL30348361 0.89 DYRK1A (0.38) DYRK1ACLK2CLK3MAP3K11BRD4
SCHEMBL25522539 0.89 DYRK1A (0.38) DYRK1ACLK2CLK3MAP3K11BRD4
SCHEMBL25522655 0.87 MAP3K11 (0.41) DYRK1ACLK2CLK3MAP3K11BRD4
SCHEMBL30347890 0.87 MAP3K11 (0.41) DYRK1ACLK2CLK3MAP3K11BRD4
SCHEMBL25196025 0.86 MAPK8 (0.36) DYRK1ACLK2CLK3MAP3K11BRD4
SCHEMBL30347848 0.85 BRD4 (0.38) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL25557327 0.85 BRD4 (0.38) DYRK1ACLK2CLK3BRD4DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback